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In earlier publications (1) we called attention to the increasing use of quinoline
compounds as topical therapeutic agents in cutaneous diseases, and we reported
our experiences with a previously untested compound, 5, 7-diiodo-8-hydroxy-
quinoline (hereafter called Diodoquin). While the index of sensitization of the
various quinolines has never been precisely established, sensitization occurred
only once in our own series of 150 patients treated with Diodoquin.
This report deals with investigations made on the one patient sensitized to
Diodoquin and on two patients sensitized to another quinoline compound,
5-chloro-7-iodo-8-hydroxyquinoline (hereafter called Vioform). The objectives
of the investigations were (1) to demonstrate that group sensitivity exists
among the halogenated hydroxyquinolines used therapeutically; (2) to identify
the chemical fraction of the halogenated hydroxyquinoline molecule required
to form the antigenic complex; (3) to explore the possibility that the sensitiza-
tion is due to a common degradation product of the substituted quinolines; and
(4) to determine whether the dermatitis can be re-elicited by oral administra-
tion of the halogenated hydroxyquinolines.
DESCRIPTiON OF PATIENTS
Patient S is a white man, 25 years old, who was admitted to the hospital with
an extensive infectious eczematoid dermatitis superimposed on a seborrheic
dermatitis. He was seen by the resident physician in the evening of the admis-
sion day and an ointment of 3 per cent Diodoquin in aquaphor was prescribed.
By the following morning the patient had developed a severe, eczematous,
contact-type dermatitis in all areas to which the ointment had been applied.
When questioned the patient recalled that he suffered a similar episode of
dermatitis about one year previously, after treatment with 3 per cent Vioform
ointment.
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Patient L is a white man, 22 years old, who was admitted to t:he hospital with
a severe, generalized atopic dermatitis. He was treated with several different
topical therapeutic agents, always with satisfactory tolerance if not remarkable
benefit. However, after the repeated use of an ointment consisting of 3 per cent
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Vioform in aquaphor it was noted that the eruption, which at first improved,
suddenly became decidedly worse. Patch tests with the ointment gave a strongly
positive reaction.
Patient D is a white man, 29 years old, who was admitted to the hospital
with an eczematous, contact-type dermatitis of the feet that was subsequently
proved to be due to the cement substance in the lining of his shoes. In the
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course of treatment 3 per cent Diodoquin in aquaphor was employed After
applying this ointment for about one week a dermatitis appeared and patch
tests confirmed the presence of sensitivity to the ointment.
DESCRIPTION OF CHEMICALS USED IN INVESTIGATIONS
The structural formulas of the various quinoline compounds investigated
are shown in Figure 1. The basic member of the group is unsubstituted quinoline.
Iso-quinoline is an isomer of quinoline, while quinaldine is a substituted quino-
line having a methyl radical in position 2. The only halogenated quinoline
available for study was 2-chioroquinoline, which has a chlorine radical in posi-
tion 2, but no hydroxyl radical. Two non-halogenated hydroxyquinolines were
a
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tested: 2-hydroxyquinoline, whose hydroxyl radical is in position 2, and 8-
hydroxyquinoline, whose hydroxyl radical is in position 8 as it is in the thera-
peutic agents that caused sensitization.
Four halogenated hydroxyquinolines were tested. Three are 8-hydroxyquino-
lines that differ only in their halogen content. Thus, Diodoquin has two iodine
radicals, in positions 5 and 7; Vioform has a chlorine radical in position 5 and
an iodine radical in position 7; and, Quinolor contains three quinoline com-
pounds, one having a single chlorine radical in position 5, the second a single
chlorine radical in position 7, and the third two chlorine radicals, in positions
5 and 7. Sterosan has the distinction of being an hydroxyquinaldine, having
an hydroxyl radical in position 8, a methyl radical in position 2, and a single
chlorine radical in position 5.
In Figure 2 are shown the structural formulas of pyridine and the three
carboxylated pyridines that were tested. It is evident that the structu"e of
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pyridine is identical with the nitrogen-bearing fraction of qumoline. Since
in vitro oxidation of quinoline with potassium permanganate destroys the
benzene nucleus resulting in the formation of pyridine-2 ,3-dicarboxylic acid
(quinolinic acid), (2) it was considered possible that similar degradation might
take place in vivo.
In Table 3 is listed a group of miscellaneous drugs that were tested for various
reasons that will be explained later.
PROCEDTJRE AND RESULTS OF TESTS
The usual procedure of patch testing was employed, most of the preparations
being incorporated in a bland ointment (aquaphor) in varying concentrations.
Tests for group sensitivity among the halogenated hydroxyquinolines
Four halogenated hydroxyquinolines were tested, the Compound Quinolor
and Sterosan ointments being used as marketed, and Vioform and Diodoquin
as ointments of 3 to 10 per cent strength in aquaphor.
Reference to Table 1 shows that all three patients reacted positively to the
four halogenated hydroxyquinolines, although the intensity of the reaction
varied. The strongest reactions occurred with Vioform and Quinolor, the weakest
with Diodoquin and Sterosan. These results indicate the presence of group
sensitivity among the four halogenated hydroxyquinolines tested.
Tests to determine the necessity for the halogen and/or hydroxyl radicals
to the reaction
Quinoline, iso-quinoline, and quinaldine were tested as ointments of 3 per
cent concentration in aquaphor.
Reference to Table 1 shows that the three patients gave consistently negative
reactions to these drugs. These results indicate that either the hydroxyl radical,
or the halogen radical, or both radicals are necessary to the sensitization.
Tests to determine the necessity for the halogen to the reaction
Patch tests were made with 3 per cent concentrations of 8-hydroxyquinoline
and 2-hydroxyquinoline in aquaphor. Patient L failed to react to the 3 per
cent concentration, and was later tested with 5 and 10 per cent concentrations
of 8-hydroxyquinoline. Reference to Table 1 shows that patients S and D re-
acted strongly to 8-hydroxyquinoline, while patient D alone reacted to 2-hy-
droxyquinoline. Patient L failed to react to either of the two hydroxyquinolines,
even to the 5 and 10 per cent concentrations of 8-hydroxyquinoline.
Reference to Table 1 shows that all three patients gave negative reactions
to 2-chloroquinoline, which was tested as an ointment of 5 per cent strength
in aquaphor.
Reference to Table 3 shows that tests with various iodine compounds (tinc-
ture of iodine, potassium iodide, iodoform, and thymol iodide) gave negative
reactions in all three patients.
These results suggest that the hydroxyl, and not the halogen, radical is
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essential to the sensitization. The inconsistent results in the case of patient
L will be discussed in the comment.
Tests for sensitivity to possible degradation products of the hydroxyquinolines
These tests were carried out with 5 per cent concentrations in aquaphor of
pyridine, a-picolinic acid (2-pyridine-carboxylic acid), nicotinic acid (3-pyridine-
carboxylic acid), and quinolinic acid (pyridine-2 ,3-dicarboxylic acid). Some
retesting of quinolinic acid was also performed with 10 per cent concentrations.
TABLE 1
Results of patch tests with quinoline and derivatives
NAME OP DRUG
PATIENTS
S L D
Quinoline
Iso-Quinoline
Quinaldine
2-Chioroquinoline
8-Hydroxyquinoline
2-Hydroxyquinoline
Vioform
Diodoquin
Quinolor
Sterosan
0
0
0
0
4+
0
4+
4+
4+
4+
0
0
0
0
0
0
4+
2+
3+
1+
0
0
0
0
4+
3+
4+
2+
4+
2+
TABLE 2
Results of patch tests with pyridine and derivatives
NAME OF DRUG
PATIENTS
S L D
Pyridine
a-picolinic acid
Nicotinic acid
Quinolinic acid
0
3+
2+
3+
0
2+
1+
3+
0
4+
4+
3+
Reference to Table 2 shows that all three patients gave negative reactions
with pyridine and positive reactions of varying degree with the three carboxy-
lated pyridines. These results will be discussed in the comment.
Test to determine ability to re-elicit the dermatitis by oral administration of the drug
After his skin had cleared patient S ingested a single tablet of Diodoquin
containing 210 mg. of 5, 7-diiodo-8-hydroxyquinoline. A severe recrudescence
of the eczematous dermatitis appeared within 12 hours after ingestion of the
tablet. We did not feel justified in repeating this procedure with the other
patients under study. This result indicates that the eczematous contact-type
dermatitis caused by the halogenated hydroxyquinolines can be re-elicited by
oral administration of these drugs.
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Control tests
Patch tests were also made on the three patients with resorcinol (which
resembles the benzene nucleus of the hydroxyquinoline structure), crude coal
tar (which contains minute amounts of quinohines) and aquaphor. Reference
to Table 3 shows that these tests gave negative reactions in all patients.
Ten patients suffering from a variety of skin diseases were used as controls.
None was known to be sensitive to any of the chemicals under investigation.
They were patch tested with all drugs listed in Tables I and 2 for an initial
48 hour period and, after an interval of two weeks, for a second 48 hour period.
No positive reactions occurred in any of the control patients.
TABLE 3
Results of patch tests with halogens and other compounds
PATIENTS
NASE OF DRUG
S L D
0Resorcinol 0 0
Tincture of iodine 0 0 0
Potassium iodide 0 0 0
lodoform 0 0 0
Thymol iodide 0 0 0
Crude coal tar 0 0 0
Aquaphor 0 0 0
COMMENTS
The first objective of the study—to demonstrate that group sensitivity
exists among the halogenated hydroxyquinolines tested—was confirmed by
the findings. Thus, patient ID, originally sensitized to Diodoquin, reacted posi-
tively to patch tests with Vioform, Quinolor, and Sterosan; and patients S and
L, originally sensitized to Vioform, reacted positively to patch tests with Diodo-
quin, Quinolor, and Sterosan.
The second objective was to identify the chemical fraction of the halogenated
hydroxyquinoline molecule required to form the antigenic complex. It is evident
that the chemical structure which is common to the reactive forms is that of a
substituted quinoline. The negative patch tests with quinoline, iso-quinoline,
and quinaldine indicate that substitution of an hydrogen by an hydroxyl or
halogen is required for elicitation of the reaction. That the chemical character
of the substituent rather than its position is the important factor is, to some
extent, supported by the fact that patient D reacted to 2-hydroxyquinoline
and not to 2-chioroquinoline or quinaldine (2-methyiquinohine). Unfortunately,
similar inferences cannot be drawn with regard to position 8, since all com-
pounds tested had an hydroxyl radical in this situation.
The substituent may serve (1) to increase the structural complementariness
of the compound with respect to the antibody or (2) to render the compound
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susceptible of conversion to the appropriate antigenically active form. The
former concept seems unlikely since compounds such as the carboxylated pyri-
dines, which are structurally very dissimilar to the halogenated hydroxyquino-
lines, were capable of eliciting reactions, while structurally similar compounds,
as unsubstituted quinolines and 2-chloroquinoline, failed to do so. The latter
concept appears to be more compatible with the data. What chemical form
the antigen actually assumes is not apparent from these data, but that it may
be an oxidation product of halogenated hydroxyquinoline is suggested by the
positive reactions obtained with the carboxylated pyridines.
That the halogen substituent itself is not the antigenic determinant is clear
from the negative reactions with various iodine compounds and the positive
reactions with the four halogenated hydroxyquinolines, whether the substituent
was iodine or chlorine. Moreover, positive reactions occurred in two patients
with hydroxyquinoline in the absence of halogen.
It is difficult to explain why patient L failed to react to 8-hydroxyquinoline,
although his reactions otherwise paralleled those of the other patients. It is
possible that this drug was poorly absorbed through his skin; or, if adequately
absorbed, that it was unable to combine with protein to form an antigenic
complex, or that it did combine with protein but at so slow a tempo or to so
slight a degree that the resultant quantity of antigenic complex was insufficient
to cause a visible reaction Similar speculations are necessary to attempt to
explain the fact that patient D alone reacted positively to 2-hydroxyquinoline.
The third objective was to explore the possibility that the sensitization was
due to a common degradation product of the substituted quinolines. That this
may be the case is suggested by the positive reactions obtained in the three
patients with the carboxylated pyridines. There are three possible explanations
for these reactions: (1) The antibody formed to halogenated hydroxyquinoline
is also capable of combining with the antigen formed by the carboxylated
pyridines; or (2) the halogenated hydroxyquinolines do not become antigenic
and evoke antibody production, but degrade into carboxylated pyridines which
become the active antigen; or (3) the halogenated hydroxyquinolines engender
two different antibodies simultaneously, one to the intact molecule, the other
to carboxylated pyridines into which the quinoline molecule degrades in whole
or in part. These findings have future implications as to possible reactions of
"cross-sensitization" with other drugs, and recall the concept of Mayer (3)
that "cross-sensitivity" among certain aromatic amines and nitro derivatives,
azo-dyes, sulfonamides, p-aminobenzoic acid and its derivatives is due to the
fact that they metabolize into a common antigenically active compound, prob-
ably of quinone structure
The fourth objective was to determine whether contact-type dermatitis
induced by cutaneous application of halogenated hydroxyquinolines can be
re-elicited by oral administration of the drugs This aspect was tested only in
patient S and it was shown that the eruption was re-elicited in severe form by
the ingestion of a small amount of the drug.
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SUMMARY
1. In two patients spontaneously sensitized to Vioform and one to Diodoquin
by cutaneous application, positive reactions were obtained to patch tests with
Vioform, Diodoquin, Quinolor, and Sterosan. This indicates the existence of
group sensitivity to the halogenated hydroxyquinolines.
2. While it was not possible to identify the chemical fraction of the halogenated
hydroxyquinolines that formed the antigenic complex, it became clear that a
substituted quinoline was required. It was shown that the halogen substituent
was not important but that the hydroxyl substituent appeared to be essential.
3. Positive patch test reactions were obtained in all patients with three
carboxylated pyridines, and it is suggested that the halogenated hydroxy-
quinolines degrade into carboxylated pyridines which form the actual antigenic
complex.
4. One patient was given a single tablet of Diodoquin (210 nig. of the drug)
by mouth after his skin had cleared and this led to a prompt and severe recur-
rence of the dermatitis.
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